AtriCure, Inc. Stock 12‑Month Price Target Raised to $64.86, Implies 7% Upside

What happened

Analysts raised AtriCure’s average 12-month share price target from $61.71 to $64.86. Based on the Nov. 3 closing price, the new target implies about 7% potential upside. Forecasts range from $55 to $70, and the rating remains Buy among eight analysts.

Confirmed

Global impact / market context

A higher target signals that analysts, on average, now see more potential share-price appreciation, which may influence investor expectations and positioning. The target is a forecast, not a guarantee; the wide range of estimates also shows that analysts differ about AtriCure’s prospects.

Analyst inference

The update reports estimates from seven analysts for the average target, while the Buy consensus covers eight analysts: six Buys, two Holds, and no Sells. The article gives no reason for the increase or company operating results, so it does not establish a business change.

Confirmed

What to watch

1. Check subsequent analyst target updates and whether the average continues to rise or reverses; the article provides no explanation for the change in estimates. Analyst inference
2. Compare future company results and outlook with analyst expectations to see whether revenue, costs, or cash available support the higher target. Analyst inference
3. Watch whether the eight-analyst rating mix changes from six Buys, two Holds, and no Sells, as that would show a shift in published recommendations. Analyst inference

Evidence

• Original source link unavailable